<SEC-DOCUMENT>0001213900-21-015427-index.html : 20210315
<SEC-HEADER>0001213900-21-015427.hdr.sgml : 20210315
<ACCEPTANCE-DATETIME>20210315171627
ACCESSION NUMBER:		0001213900-21-015427
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210315
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210315
DATE AS OF CHANGE:		20210315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RELMADA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001553643
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				455401931
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39082
		FILM NUMBER:		21742501

	BUSINESS ADDRESS:	
		STREET 1:		880 3RD AVENUE, 12TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		646 876 3459

	MAIL ADDRESS:	
		STREET 1:		880 3RD AVENUE, 12TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CAMP NINE, INC.
		DATE OF NAME CHANGE:	20120706
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea137714-8k_relmada.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
Document 1 - file: ea137714-8k_relmada.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea137714ex99-1_relmada.htm
<DESCRIPTION>CONCLUSIONS OF PRECLINICAL ABUSE STUDIES ON REL-1017 (ESMETHADONE)
<TEXT>
Document 2 - file: ea137714ex99-1_relmada.htm

</DOCUMENT>
</SEC-DOCUMENT>